Cryopyrin-Associated Periodic Syndrome (CAPS) Caused by c.943A>G Variant of NLRP3 Gene: Clinical Case

Background. Cryopyrin-associated periodic syndromes is a group of rare congenital autoinflammatory diseases such as familial cold autoinflammatory syndrome, Muckle-Wells syndrome and chronic infantile neurological cutaneous articular syndrome. These syndromes are considered as clinical variants of one disease with different intensity of clinical features and severity of pathologic process. The onset of these syndromes is usually on the first year of life, and they start with fever, urticarial rash, various variants of joint diseases (from arthralgia to residual and persistent arthritis) and nervous system disturbances. There are only single case reports of cryopyrin-associated periodic syndromes in Russia.

Clinical Case Description. The disease onset was at the age of 1 year 8 months with fever and rash as well as generalized joint syndrome. Autoinflammatory syndrome was suspected due to to results of blood tests, MRI, molecular genetic testing. Exons 2, 3 and 4 of TNFRSF1A gene and exon 4 of NLRP3 gene with nearby introns were studied with the method of direct automated sequencing. The c.943A>G variant in heterozygous state in NLRP3 gene was revealed. The child was treated with IL-1 beta inhibitor (canakinumab) with positive effect.

Conclusion. Diagnostics of cryopyrin-associated periodic syndrome in children is the serious challenge. Timely decision with help of molecular genetic methods is crucial for successful target therapy.

1. Detskaya revmatologiya. Atlas. Ed by Baranov AA, Alekseeva EI. Moscow: Pediatr; 2015. pp. 282-290. (In Russ).

2. Quartier P, Rodrigues F, Georgin-Lavialle S. [Cryopyrin-associated periodic syndromes. (In French).] Rev Med Interne. 2018;39(4): 287-296. doi: 10.1016/j.revmed.2017.09.002.

3. Lasiglie D, Mensa-Vilaro A, Ferrera D, et al. Cryopyrin-associated periodic syndromes in italian patients: evaluation of the rate of somatic NLRP3 mosaicism and phenotypic characterization. J Rheumatol. 2017;44(11):1667-1673. doi: 10.3899/jrheum.170041.

4. Li C, Tan X, Zhang J, et al. Gene mutations and clinical phenotypes in 15 Chinese children with cryopyrin-associated periodic syndrome (CAPS). Sci China Life Sci. 2017;60(12):1436-1444. doi: 10.1007/s11427-017-9246-4.

5. McGeough MD, Wree A, Inzaugarat ME, et al. TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. J Clin Invest. 2017;127(12): 4488-4497. doi: 10.1172/JCI90699.

6. Salugina SO, Fedorov ES, Kuzmina NN. Current approaches to diagnosis, treatment, and monitoring in patients with cryopyrin-associated periodic syndromes (CAPS). Modern Rheumatology Journal. 2016;10(2):4-11. (In Russ). doi: 10.14412/1996-7012-2016-2-4-11.

7. Gattorno M. Cryopyrin associated periodic syndrome. Current Pediatrics. 2013;12(1):57-62. (In Russ). doi: 10.15690/vsp.v12i1.558.

8. Кузьмина Н.Н., Салугина С.О., Федоров Е.С. Аутовоспалительные заболевания и синдромы у детей. — М.: ИМА-Пресс; 2012. — 104 с. [Kuzmina NN, Salugina SO, Federov ES. Autovospalitelnye zabolevaniya i sindromy u detei. Moscow: IMA-Press; 2012. 104 р. (In Russ).]

9. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46(12): 3340-3348. doi: 10.1002/art.10688.

10. Cazeneuve C, Ajrapetyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet. 2000;67(5):1136-1143. doi: 10.1016/S0002-9297(07)62944-9.

11. Chae JJ, Centola M, Aksentijevich I, et al. Isolation, genomic organization, and expression analysis of the mouse and rat homologs of MEFV, the gene for familial mediterranean fever. Mamm Genome. 2000;11(6):428-435. doi: 10.1007/s003350010082.

12. Federici S, Sormani MP Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015;74(5):799-805. doi: 10.1136/annrheumdis-2014-206580.

13. Kostik MM, Snegireva LS, Dubko MF, et al. How to identity a patient with autoinflammatory syndrome: clinical and diagnostic algorithms. Modern Rheumatology Journal. 2013;7(3):14-20. (In Russ). doi: 10.14412/1996-7012-2013-5.

14. Terreri MT, Bernardo WM, Len CA, et al. Guidelines for the management and treatment of periodic fever syndromes: Cryopyrin-associated periodic syndromes (cryopyrinopathies — CAPS). Rev Bras Reumatol Engl Ed. 2016;56(1):44-51. doi: 10.1016/j.rbre.2015.08.020.

15. Elmi AA, Wynne K, Cheng IL, et al. Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome. Pediatr Rheumatol Online J. 2019;17(1):36. doi: 10.1186/s12969-019-0335-4.

16. Brogan PA, Hofer M, Kuemmerle-Deschner JB, et al. Rapid and sustained long-term efficacy and safety of canakinumab in patients with cryopyrin-associated periodic syndrome ages five years and younger. Arthritis Rheumatol. 2019, Jun 4. doi: 10.1002/art.41004.

17. Ruperto N, Brunner HI, Quartier P, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018;77(12):1710-1719. doi: 10.1136/annrheumdis-2018-213150.

18. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416-2425. doi: 10.1056/NEJMoa0810787.

19. Sleptsova TV, Alexeeva EI, Savostyanov KV, et al. Experience in application of canakinumab in patients with cryopyrin-associated syndrome (syndrome CINCA/NOMID). Current pediatrics. 2014;13(3):97-102. (In Russ). doi: 10.15690/vsp.v13i3.1035.

20. Eskola V, Pohjankoski H, Kroger L, et al. Cryopyrin-associated periodic syndrome in early childhood can be successfully treated with interleukin-1 blockades. Acta Paediatr. 2018;107(4):577-580. doi: 10.1111